Gynecologic Cancer News

The FDA granted fast track designation to IN10018 for treatment of platinum-resistant ovarian cancer.

The FDA granted fast track designation to STRO-002 for treatment of certain women with advanced gynecologic cancer.

The FDA granted accelerated approval to dostarlimab-gxly for adults with mismatch repair-deficient recurrent or advanced solid tumors that progressed on or after prior treatment and who have no satisfactory alternative therapies.

Researchers at Texas A&M University have developed an organ-on-a-chip that they said could change the way clinicians approach ovarian and other cancer treatment.

A trial designed to evaluate maveropepimut-S for women with advanced recurrent ovarian cancer demonstrated encouraging activity, according to the agent’s manufacturer.

Cancer Health, an online resource for patients with cancer, recognized Erin Kobetz, PhD, MPH, for her research on identifying and overcoming racial disparities in health care.

The FDA granted priority review to pembrolizumab as adjuvant therapy for certain patients with renal cell carcinoma, according to the agent’s manufacturer.

Many transgender men and nonbinary people assigned female at birth, or TMNB, reported barriers to cervical cancer screening, according to results of a cross-sectional survey of these underserved populations.

Transvaginal ultrasound used to determine appropriateness of endometrial cancer biopsy missed nearly five times more cases of the disease among Black women vs. white women, according to a simulated cohort study published in JAMA Oncology.

Although 5-year survival rates have increased for multiple cancer types among adolescents and young adults, little or no improvement has been observed for some common malignancies in this population, according to findings published in Cancer.